search
Back to results

Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme

Primary Purpose

Osteoporosis

Status
Active
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Documentation
Video
Sponsored by
CHU de Quebec-Universite Laval
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Osteoporosis focused on measuring Osteoporosis, Fragility fracture, Women, Randomised control trial, Patient education, Diagnosis, Treatment

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female, aged 50 years and over. Not residing in a long-term care hospital before the fracture. Able to understand the programme information and consent form. Must voluntarily accept to participate in this programme and sign the consent form. Participants must have a fragility or traumatic fracture of one of the following sites: wrist, forearm, humerus, scapula, clavicle, sternum, thoracic or lumbar vertebrae, pelvis, sacrum, hip, femur, proximal and distal tibia, fibula (including ankle), and foot. Participants must be able to answer the questionnaires via phone interviews Exclusion Criteria: Unable to understand the purpose of the programme. Participants with a traumatic fracture of one of the following sites: cervical, skull and face, hand and finger, toe, metatarsus, and patella. Pathological fracture. Women currently participating in a clinical trial requiring them to take a medication for osteoporosis.

Sites / Locations

  • CHUdeQuebec, CHUL

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Documentation

Video

Arm Description

Written educational material on osteoporosis for the participant and the physician.

A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.

Outcomes

Primary Outcome Measures

The present diagnostic and treatment rates of osteoporosis 6 months after a fragility fracture
The osteoporosis diagnostic rate and on the osteoporosis pharmacological treatment rate 12 months after the educational interventions
The average 5-year, 10-year, 15-year, and 20-year probabilities of a fragility fracture by age, site of previous fragility fracture, and type of ROCQ intervention.

Secondary Outcome Measures

Changes of modifiable risk factors for osteoporosis 12 months after the intervention
Proportion of fragility versus traumatic fractures.
Health care resource utilization associated with specific types of fragility fracture and recurrent fractures.
Assess health utility index (EQ-5D) after a fragility fracture.
Satisfaction with the process of care before and after implementing ROCQ's interventions.
One-year mortality rate following a fragility fracture.
Persistence to pharmacological treatment 12 months after the intervention
Incidence of recurrent fracture and health care resources utilization between women who previously had a fragility fracture and those who had a traumatic fracture.

Full Information

First Posted
July 28, 2006
Last Updated
November 17, 2017
Sponsor
CHU de Quebec-Universite Laval
Collaborators
Merck Frosst Canada Ltd., Sanofi, Procter and Gamble, Amgen, Eli Lilly and Company, Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00359047
Brief Title
Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme
Official Title
Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 2003 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
CHU de Quebec-Universite Laval
Collaborators
Merck Frosst Canada Ltd., Sanofi, Procter and Gamble, Amgen, Eli Lilly and Company, Novartis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the ROCQ programme is to improve the use of evidence based osteoporosis diagnostic and treatment strategies for women 50 years and over who have suffered a fragility fracture. This objective will be achieved by concentrating on a realistic evaluation of the present diagnosis and treatment rate of osteoporosis following a fragility fracture and comparing it to an optimal situation (care gap) and proposing interventions that promote new approaches to treating osteoporosis by health professionals as well as providing targeted interventions for the patient. The efficacy of these interventions will be evaluated using a randomized control design.
Detailed Description
ROCQ is a patient health-management programme and prospective cohort study. Within the ROCQ programme, educational interventions to improve osteoporosis management will be evaluated using a randomized-control design. The programme is composed of a promotional campaign, three main phases and a 20-year follow-up. At phase 1, 0 to 16 weeks after the fracture, participants with fragility and traumatic fractures will be recruited and will be asked information regarding their fracture. At phase 2, 6 to 8 months after the fracture, all participants will complete questionnaires to evaluate demographic and clinical features, risk factors for osteoporosis, co-morbidities, status of diagnosis and treatment, and the EQ-5D. The current medical management of osteoporosis (or the care gap in diagnosis and treatment) will be measured using this questionnaire at phase 2. Once the phase 2 questionnaire has been completed, Only participants with fragility fractures will be randomized to one of the three following educational intervention groups: 1) the Educational Video Group, 2) the Documentation Group, or 3) the Control Group. At phase 3, 12 to 14 months after randomization, the effectiveness of the interventions will be assessed by re-administering the questionnaires to participants who experienced a fragility fracture at baseline. The questionnaires evaluate the status of diagnosis and treatment of osteoporosis, modifiable risk factors and the health-related quality of life (EQ-5D). The impact of the interventions on the participants will be assessed by comparing diagnosis and treatments rates in each intervention arm. If the long-term viability of the programme is secured, participants with fragility and traumatic fractures will be followed for a maximum period of 20 years using specific encoded personal data contained in the RAMQ and Quebec's drug plan databases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis
Keywords
Osteoporosis, Fragility fracture, Women, Randomised control trial, Patient education, Diagnosis, Treatment

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2830 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Documentation
Arm Type
Experimental
Arm Description
Written educational material on osteoporosis for the participant and the physician.
Arm Title
Video
Arm Type
Experimental
Arm Description
A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
Intervention Type
Behavioral
Intervention Name(s)
Documentation
Intervention Description
Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
Intervention Type
Behavioral
Intervention Name(s)
Video
Intervention Description
Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
Primary Outcome Measure Information:
Title
The present diagnostic and treatment rates of osteoporosis 6 months after a fragility fracture
Time Frame
June 2007
Title
The osteoporosis diagnostic rate and on the osteoporosis pharmacological treatment rate 12 months after the educational interventions
Time Frame
June 2007
Title
The average 5-year, 10-year, 15-year, and 20-year probabilities of a fragility fracture by age, site of previous fragility fracture, and type of ROCQ intervention.
Time Frame
July 2009
Secondary Outcome Measure Information:
Title
Changes of modifiable risk factors for osteoporosis 12 months after the intervention
Time Frame
September 2009
Title
Proportion of fragility versus traumatic fractures.
Time Frame
June 2007
Title
Health care resource utilization associated with specific types of fragility fracture and recurrent fractures.
Time Frame
September 2010
Title
Assess health utility index (EQ-5D) after a fragility fracture.
Time Frame
September 2010
Title
Satisfaction with the process of care before and after implementing ROCQ's interventions.
Time Frame
June 2010
Title
One-year mortality rate following a fragility fracture.
Time Frame
May 2009
Title
Persistence to pharmacological treatment 12 months after the intervention
Time Frame
October 2009
Title
Incidence of recurrent fracture and health care resources utilization between women who previously had a fragility fracture and those who had a traumatic fracture.
Time Frame
November 2010

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female, aged 50 years and over. Not residing in a long-term care hospital before the fracture. Able to understand the programme information and consent form. Must voluntarily accept to participate in this programme and sign the consent form. Participants must have a fragility or traumatic fracture of one of the following sites: wrist, forearm, humerus, scapula, clavicle, sternum, thoracic or lumbar vertebrae, pelvis, sacrum, hip, femur, proximal and distal tibia, fibula (including ankle), and foot. Participants must be able to answer the questionnaires via phone interviews Exclusion Criteria: Unable to understand the purpose of the programme. Participants with a traumatic fracture of one of the following sites: cervical, skull and face, hand and finger, toe, metatarsus, and patella. Pathological fracture. Women currently participating in a clinical trial requiring them to take a medication for osteoporosis.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacques P Brown, MD
Organizational Affiliation
CHU de Quebec
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHUdeQuebec, CHUL
City
Quebec
ZIP/Postal Code
G1V 4G2
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
17766187
Citation
Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Brown JP. Recognizing osteoporosis and its consequences in Quebec (ROCQ): background, rationale, and methods of an anti-fracture patient health-management programme. Contemp Clin Trials. 2008 Mar;29(2):194-210. doi: 10.1016/j.cct.2007.07.007. Epub 2007 Jul 24.
Results Reference
background
PubMed Identifier
19333675
Citation
Bessette L, Jean S, Davison KS, Roy S, Ste-Marie LG, Brown JP. Factors influencing the treatment of osteoporosis following fragility fracture. Osteoporos Int. 2009 Nov;20(11):1911-9. doi: 10.1007/s00198-009-0898-x. Epub 2009 Mar 31.
Results Reference
result
PubMed Identifier
24519745
Citation
Beaudoin C, Bessette L, Jean S, Ste-Marie LG, Brown JP. The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture. Osteoporos Int. 2014 Jul;25(7):1821-30. doi: 10.1007/s00198-014-2618-4. Epub 2014 Feb 12.
Results Reference
result
PubMed Identifier
21927921
Citation
Bessette L, Jean S, Lapointe-Garant MP, Belzile EL, Davison KS, Ste-Marie LG, Brown JP. Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporos Int. 2012 Jun;23(6):1757-68. doi: 10.1007/s00198-011-1785-9. Epub 2011 Sep 17.
Results Reference
result
PubMed Identifier
21311871
Citation
Bessette L, Davison KS, Jean S, Roy S, Ste-Marie LG, Brown JP. The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial. Osteoporos Int. 2011 Dec;22(12):2963-72. doi: 10.1007/s00198-011-1533-1. Epub 2011 Feb 11.
Results Reference
result
PubMed Identifier
17641811
Citation
Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Brown JP. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008 Jan;19(1):79-86. doi: 10.1007/s00198-007-0426-9. Epub 2007 Jul 20.
Results Reference
result

Learn more about this trial

Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme

We'll reach out to this number within 24 hrs